title: Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts.
abstract: In vivo production and systemic delivery of therapeutic antibodies by engineered cells might advantageously replace injection of purified antibodies for treating a variety of life-threatening diseases, including cancer, acquired immunodeficiency syndrome, and autoimmune diseases. We report here that skin fibroblasts retrovirally transduced to express immunoglobulin genes can be used for sustained long-term systemic delivery of cloned antibodies in immunocompetent mice. Importantly, no anti- idiotypic response against the ectopically expressed model antibody used in this study was observed. This supports the notion that skin fibroblasts can potentially be used in antibody-based gene/cell therapy protocols without inducing any adverse immune response in treated individuals.
authors.affiliation: Institut de Génetique Moléculaire, UMR 5535, CNRS, Montpellier, France.
authors.forename: D
authors.initials: D
authors.lastname: Noël
authors.forename: M
authors.initials: M
authors.lastname: Pelegrin
authors.forename: F
authors.initials: F
authors.lastname: Brockly
authors.forename: A H
authors.initials: AH
authors.lastname: Lund
authors.forename: M
authors.initials: M
authors.lastname: Piechaczyk
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics* / Q000627:therapeutic use*; D000917:Antibody Formation / Q000235:genetics; D004195:Disease Models, Animal; D005347:Fibroblasts / Q000276:immunology*; D015316:Genetic Therapy; D006801:Humans; D007121:Immunocompetence; D051379:Mice / Q000276:immunology*; D012867:Skin / Q000166:cytology*
chemical_list: D000911:Antibodies, Monoclonal